{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T20:40:51Z","timestamp":1696538451295},"reference-count":71,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.idc.2012.08.005","type":"journal-article","created":{"date-parts":[[2012,10,17]],"date-time":"2012-10-17T17:06:01Z","timestamp":1350493561000},"page":"967-978","source":"Crossref","is-referenced-by-count":1,"title":["Hepatitis C Virus Drug Resistance"],"prefix":"10.1016","volume":"26","author":[{"given":"David L.","family":"Wyles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.idc.2012.08.005_bib1","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.idc.2012.08.005_bib2","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.idc.2012.08.005_bib3","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.idc.2012.08.005_bib4","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"Pt 11","key":"10.1016\/j.idc.2012.08.005_bib5","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1099\/vir.0.80401-0","article-title":"Genetic diversity and evolution of hepatitis C virus: 15 years on","volume":"85","author":"Simmonds","year":"2004","journal-title":"J\u00a0Gen Virol"},{"issue":"8","key":"10.1016\/j.idc.2012.08.005_bib6","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1073\/pnas.88.8.3392","article-title":"Nucleotide sequence and mutation rate of the H strain of hepatitis C virus","volume":"88","author":"Ogata","year":"1991","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"4","key":"10.1016\/j.idc.2012.08.005_bib7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrg2323","article-title":"Rates of evolutionary change in viruses: patterns and determinants","volume":"9","author":"Duffy","year":"2008","journal-title":"Nat Rev Genet"},{"issue":"5386","key":"10.1016\/j.idc.2012.08.005_bib8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in\u00a0vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"issue":"30","key":"10.1016\/j.idc.2012.08.005_bib9","doi-asserted-by":"crossref","first-page":"30ra32","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus","volume":"2","author":"Rong","year":"2010","journal-title":"Sci Transl Med"},{"issue":"24","key":"10.1016\/j.idc.2012.08.005_bib10","doi-asserted-by":"crossref","first-page":"13910","DOI":"10.1073\/pnas.96.24.13910","article-title":"Mutation rates among RNA viruses","volume":"96","author":"Drake","year":"1999","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"5255","key":"10.1016\/j.idc.2012.08.005_bib11","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","article-title":"HIV-1 dynamics in\u00a0vivo: virion clearance rate, infected cell life-span, and viral generation time","volume":"271","author":"Perelson","year":"1996","journal-title":"Science"},{"issue":"7053","key":"10.1016\/j.idc.2012.08.005_bib12","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/nature04077","article-title":"Unravelling hepatitis C virus replication from genome to function","volume":"436","author":"Lindenbach","year":"2005","journal-title":"Nature"},{"issue":"6510","key":"10.1016\/j.idc.2012.08.005_bib13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/373123a0","article-title":"Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection","volume":"373","author":"Ho","year":"1995","journal-title":"Nature"},{"issue":"5341","key":"10.1016\/j.idc.2012.08.005_bib14","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in\u00a0patients on highly active antiretroviral therapy","volume":"278","author":"Finzi","year":"1997","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.idc.2012.08.005_bib15","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/8394","article-title":"Latent infection of CD4\u00a0+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy","volume":"5","author":"Finzi","year":"1999","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.idc.2012.08.005_bib16","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.idc.2012.08.005_bib17","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/hep.23192","article-title":"Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients","volume":"50","author":"Susser","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.idc.2012.08.005_bib18","unstructured":"Vertex Pharmaceuticals. Telaprevir 375-mg film-coated tablet for the treatment of genotype 1 chronic hepatitis C antiviral drugs advisory committee briefing document [internet]. 2011. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AntiviralDrugsAdvisoryCommittee\/UCM252562.pdf. Accessed April 29, 2011."},{"key":"10.1016\/j.idc.2012.08.005_bib19","unstructured":"Merck and Co., Inc. FDA Antiviral Drugs Advisory Committee Meeting Boceprevir Capsules (NDA 202\u2013258) Briefing Document [internet]. 2011. Available at: http:\/\/www.google.com\/url?sa=t&source=web&cd=1&sqi=2&ved=0CB0QFjAA&url=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FAdvisoryCommittees%2FCommitteesMeetingMaterials%2FDrugs%2FAntiviralDrugsAdvisoryCommittee%2FUCM252343.pdf&;ei=fhqKTuj8LIS3tgeFo9BJ&usg=AFQjCNFr9KzfbJy3xPQFkBzQkJvR2U4R2w."},{"issue":"14","key":"10.1016\/j.idc.2012.08.005_bib20","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchison","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.idc.2012.08.005_bib21","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"H\u00e9zode","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.idc.2012.08.005_bib22","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"9742","key":"10.1016\/j.idc.2012.08.005_bib23","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","article-title":"Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial","volume":"376","author":"Kwo","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.idc.2012.08.005_bib24","first-page":"6","article-title":"Characterization of resistant variants in treatment-naive and experienced genotype 1 HCV patients in phase 2 trials of telaprevir\/Peg-IFN\/RBV","volume":"5","author":"Kieffer","year":"2010","journal-title":"Reviews in Antiviral Therapy and Infectious Diseases"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2012.08.005_bib25","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(11)60010-X","article-title":"Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials","volume":"54","author":"Sullivan","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.idc.2012.08.005_bib26","first-page":"440","article-title":"Analysis of resistance-associated amino acid variants (RAVS) in non-SVR patients enrolled in a retrospective long-term follow-up analysis of boceprevir phase 3 clinical studies","volume":"54","author":"Barnard","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl 4","key":"10.1016\/j.idc.2012.08.005_bib27","article-title":"Follow-up of SVR durability and viral resistance in patients with chronic hepatitis C treated with telaprevir-based regimens: interim analysis of the EXTEND study","volume":"54","author":"Sherman","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl 4","key":"10.1016\/j.idc.2012.08.005_bib28","first-page":"436A","article-title":"Long-term follow-up of patients with chronic hepatitis c treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the EXTEND Study","volume":"52","author":"Zeuzem","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2012.08.005_bib29","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.1016\/S0168-8278(11)61204-X","article-title":"1202 characterisation of HCV variants in non-SVR patients in the REALIZE study suggests that telaprevir exhibits a consistent resistance profile irrespective of a lead-in","volume":"54","author":"De Meyer","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2012.08.005_bib30","doi-asserted-by":"crossref","first-page":"S465","DOI":"10.1016\/S0168-8278(12)61186-6","article-title":"1174 deep sequencing screening for telaprevir-resistant viral variants in previous null responders fails to identify those patients at risk of failing telaprevir plus peginterferon\/ribavirin therapy","volume":"56","author":"De Meyer","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.idc.2012.08.005_bib31","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1086\/589297","article-title":"Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an international AIDS Society-USA Panel","volume":"47","author":"Hirsch","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2012.08.005_bib32","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJMoa013552","article-title":"Antiretroviral-drug resistance among patients recently infected with HIV","volume":"347","author":"Little","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.idc.2012.08.005_bib33","doi-asserted-by":"crossref","first-page":"F17","DOI":"10.1097\/00002030-199902040-00001","article-title":"Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study","volume":"13","author":"Lorenzi","year":"1999","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.idc.2012.08.005_bib34","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1086\/314928","article-title":"Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy","volume":"180","author":"Parkin","year":"1999","journal-title":"J\u00a0Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2012.08.005_bib35","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1086\/528802","article-title":"Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects","volume":"197","author":"Kuritzkes","year":"2008","journal-title":"J\u00a0Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2012.08.005_bib36","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1128\/JCM.37.7.2291-2296.1999","article-title":"Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase","volume":"37","author":"Schuurman","year":"1999","journal-title":"J\u00a0Clin Microbiol"},{"issue":"Suppl 4","key":"10.1016\/j.idc.2012.08.005_bib37","first-page":"1429A","article-title":"TMC435 in combination with peginterferon and ribavirin in treatment-na\u00efve HCV genotype 1 patients: final analysis of the pillar phase IIB study","volume":"54","author":"Fried","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl 4","key":"10.1016\/j.idc.2012.08.005_bib38","first-page":"473","article-title":"Treatment with the second generation HCV protease inhibitor bi201335 results in high and consistent SVR rates: results from silen-c1 in treatment-na\u00efve patients across different baseline factors","volume":"54","author":"Sulkowski","year":"2011","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.idc.2012.08.005_bib39","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","article-title":"In\u00a0vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435","volume":"54","author":"Lenz","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2012.08.005_bib40","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/AAC.05166-11","article-title":"In\u00a0vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335","volume":"56","author":"Lagac\u00e9","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"17","key":"10.1016\/j.idc.2012.08.005_bib41","doi-asserted-by":"crossref","first-page":"17508","DOI":"10.1074\/jbc.M313020200","article-title":"In\u00a0vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms","volume":"279","author":"Lin","year":"2004","journal-title":"J\u00a0Biol Chem"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2012.08.005_bib42","doi-asserted-by":"crossref","first-page":"S482","DOI":"10.1016\/S0168-8278(11)61223-3","article-title":"1221 treatment outcome and resistance analysis in HCV genotype 1 patients previously exposed to tmc435 monotherapy and re-treated with tmc435 in combination with pegifn\u00ee\u00b1-2a\/ribavirin","volume":"54","author":"Lenz","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2012.08.005_bib43","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/S0168-8278(12)61197-0","article-title":"1185 characterization of HCV NS3 variants that emerged during virologic breakthrough and relapse from BI 201335 phase II silen-c2 study in PEGIFN\/RBV treatment-experienced patients","volume":"56","author":"Kukolj","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 4","key":"10.1016\/j.idc.2012.08.005_bib44","first-page":"991A","article-title":"Characterization of HCV NS3 variants that emerged during virologic breakthrough and relapse from BI201335 phase 2 SILEN-C1 study","volume":"54","author":"Kukolj","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2012.08.005_bib45","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.1016\/S0168-8278(11)61231-2","article-title":"1229 genotypic and phenotypic characterization of NS3 variants selected in HCV-infected patients treated with ABT-450","volume":"54","author":"Pilot-Matias","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2012.08.005_bib46","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0168-8278(10)60041-4","article-title":"39 MK-5172: a novel HCV NS3\/4A protease inhibitor with potent activity against known resistance mutants","volume":"52","author":"Carroll","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 4","key":"10.1016\/j.idc.2012.08.005_bib47","first-page":"531A","article-title":"Safety and antiviral activity of MK-5172, a next generation HCV NS3\/4A protease inhibitor with a broad hcv genotypic activity spectrum and potent activity against known resistance mutants, in genotype 1 and 3 HCV- infected patients","volume":"54","author":"Petry","year":"2011","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.idc.2012.08.005_bib48","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1128\/AAC.00365-06","article-title":"Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor","volume":"50","author":"Howe","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.idc.2012.08.005_bib49","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.3390\/v2102169","article-title":"Inhibitors of the hepatitis C virus RNA-dependent RNA polymerase NS5B","volume":"2","author":"Powdrill","year":"2010","journal-title":"Viruses"},{"issue":"Suppl 4","key":"10.1016\/j.idc.2012.08.005_bib50","first-page":"532A","article-title":"No detection of variants bearing NS5B S282T mericitabine (MCB) resistance mutation in DAA treatment-naive HCV genotype 1 (G1)-infected patients using ultra-deep pyrosequencing (UDPS)","volume":"54","author":"Margeridon","year":"2011","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.idc.2012.08.005_bib51","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.22549","article-title":"Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-na\u00efve patients","volume":"48","author":"Kuntzen","year":"2008","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.idc.2012.08.005_bib52","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/jac\/dkn085","article-title":"Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients","volume":"61","author":"Le Pogam","year":"2008","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"49","key":"10.1016\/j.idc.2012.08.005_bib53","doi-asserted-by":"crossref","first-page":"49164","DOI":"10.1074\/jbc.M305041200","article-title":"Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in\u00a0vitro","volume":"278","author":"Migliaccio","year":"2003","journal-title":"J\u00a0Biol Chem"},{"issue":"5","key":"10.1016\/j.idc.2012.08.005_bib54","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1128\/AAC.01317-07","article-title":"The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors","volume":"52","author":"McCown","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2012.08.005_bib55","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00054-12","article-title":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus","author":"Lam","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2012.08.005_bib56","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1517\/13543780902854194","article-title":"Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: nucleoside analogues","volume":"18","author":"Brown","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2012.08.005_bib57","doi-asserted-by":"crossref","first-page":"S481","DOI":"10.1016\/S0168-8278(12)61225-2","article-title":"1213 efficacy and safety of mericitabine (MCB) in combination with PEG-IFNA-2A\/RBV in G1\/4 treatment naive HCV patients: final analysis from the PROPEL study","volume":"56","author":"Wedemeyer","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2012.08.005_bib58","doi-asserted-by":"crossref","first-page":"S438","DOI":"10.1016\/S0168-8278(12)61125-8","article-title":"1113 electron: once daily PSI-7977 Plus RBV in HCV GT1\/2\/3","volume":"56","author":"Gane","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.idc.2012.08.005_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.idc.2012.08.005_bib60","series-title":"High rates of SVR24 for BMS-790052, an\u00a0NS5A replication complex inhibitor, in combination with PegIFN-alfa-2a and ribavirin: phase 2a trial in treatment-naive HCV genotype 1 subjects","author":"Pol","year":"2011"},{"issue":"6","key":"10.1016\/j.idc.2012.08.005_bib61","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in\u00a0vitro and in\u00a0vivo correlations","volume":"54","author":"Fridell","year":"2011","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.idc.2012.08.005_bib62","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1128\/AAC.05977-11","article-title":"Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052","volume":"56","author":"Wang","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2012.08.005_bib63","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","author":"Lok","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2012.08.005_bib64","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0168-8278(12)60028-2","article-title":"14 dual oral therapy with the NS5A inhibitor DACLATASVIR (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS-650032) in HCV genotype 1B-infected null responders or ineligible\/intolerant to peginterferon\/ribavirin","volume":"56","author":"Suzuki","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2012.08.005_bib65","doi-asserted-by":"crossref","first-page":"S464","DOI":"10.1016\/S0168-8278(12)61184-2","article-title":"1172 antiviral activity and resistance profile of the novel HCV NS5A inhibitor GS-5885","volume":"56","author":"Cheng","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.idc.2012.08.005_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2011.12.029","article-title":"A\u00a0phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C","author":"Lawitz","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2012.08.005_bib67","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/S0168-8278(12)61198-2","article-title":"1186 safety and antiviral activity of ABT-267, a novel NS5A inhibitor, during 3-day monotherapy: first study in HCV genotype-1 (GT1)-infected treatment-naive subjects","volume":"56","author":"Lawitz","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2012.08.005_bib68","first-page":"A400","article-title":"Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PegIFN\/RBV for up to 28 days in treatment na\u00efve, genotype 1 HCV subjects","volume":"52","author":"Zeuzem","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2012.08.005_bib69","doi-asserted-by":"crossref","first-page":"S540","DOI":"10.1016\/S0168-8278(11)61365-2","article-title":"1363 VX-222 with TVR alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C: zenith study interim results","volume":"54","author":"Di Bisceglie","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2012.08.005_bib70","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0168-8278(11)60065-2","article-title":"63 characterization of virologic escape in HCV genotype 1 null responders receiving a combination of the NS3 protease inhibitor BMS-650032 and NS5A inhibitor BMS-790052","volume":"54","author":"McPhee","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.idc.2012.08.005_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(10)61384-0","article-title":"Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial","author":"Gane","year":"2010","journal-title":"Lancet"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552012000815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552012000815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T21:41:31Z","timestamp":1594762891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552012000815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0891552012000815"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2012.08.005","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}